Cover Image
市場調查報告書

用子宮頸癌症診斷藥、治療藥的全球市場:診斷檢驗、手法、終端用戶、治療方法、各地區的詳細趨勢 (2014∼2020年)

Global Cervical Cancer Diagnostics and Therapeutics Market - Segmented by Diagnostic Test, By Therapeutics, End Users - Growth, Trends and Forecasts (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 353906
出版日期 內容資訊 英文 109 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
用子宮頸癌症診斷藥、治療藥的全球市場:診斷檢驗、手法、終端用戶、治療方法、各地區的詳細趨勢 (2014∼2020年) Global Cervical Cancer Diagnostics and Therapeutics Market - Segmented by Diagnostic Test, By Therapeutics, End Users - Growth, Trends and Forecasts (2018 - 2023)
出版日期: 2018年03月01日 內容資訊: 英文 109 Pages
簡介

全球子宮頸癌症相關市場 (診斷藥、治療藥等) ,2015年達到21億4000萬美元的規模,再加上2015∼2020年2∼5%的年複合成長率 (CAGR) 預計成長。根據世界衛生組織 (WHO) ,以開發中國家為中心,全球每年有27萬人女性因子宮頸癌症死亡。近幾年子宮頸抹片檢驗 (子宮頸細胞診斷檢驗) 和人類乳突病毒 (HPV) 檢驗,大腸內視鏡檢驗等早期診斷手法廣泛普及,使市場競爭變活躍同時,市場成長率也變高。在各地區中,北美各國約佔49%的市場佔有率。

本報告提供全球子宮頸癌症診斷藥、治療藥的市場相關分析,疾病概要和市場基本結構,主要的促進、阻礙因素,市場誘因、競爭力,整體市場及檢查項目別、各診斷手法、各終端用戶 (醫院,診療所,檢驗所等)、各地區的趨勢預測,市場競爭狀況,主要企業簡介等調查評估。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義
  • 推動市場要素
    • 直腸結腸癌症的篩檢檢驗用開發中產品的增加
    • 人口高齡化
    • 在一般社會的認知度上升
  • 阻礙市場要素
    • 篩檢檢驗的費用
    • 諮詢
  • 市場機會

第4章 波特的五力分析

  • 供應商談判力
  • 買主談判力
  • 企業間競爭的程度
  • 替代產品的威脅
  • 新加入廠商的威脅

第5章 市場明細

  • 各診斷方法
    • 數位式直腸婦科檢查
    • 大便潛血試驗
    • 軟性S書結腸鏡子檢驗
    • 大腸內視鏡檢驗
    • 虛擬大腸鏡檢查內視鏡檢驗
  • 各治療手法
    • 外科手術、放射治療
    • 化療
    • 標靶治療
    • 對藥物療法的抗性
  • 各地區 (北美,歐洲,亞太地區,中東、非洲等)

第6章 競爭環境

  • 企業合併、收購 (M&A)
  • 契約、產業聯盟、產業合作
  • 新產品的銷售
  • 對新加入企業的建議

第7章 企業簡介

  • Abbott Diagnostics
  • Alere
  • Beckman Coulter
  • Clinical Genomics
  • Companion Dx
  • EDP Biotech
  • Epigenomics AG
  • Exact Sciences
  • FUJIREBIO (Miraca Holdings)
  • Genomic Tree
  • Metabiomics
  • Oncocyte (Biotime)
  • Quest Diagnostics
  • Randox Laboratories
  • Siemens Healthcare
  • Volition Rx

第8章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 32066

Description

The global cervical cancer diagnostics and therapeutics market is expected to register a CAGR of 6.3% during the forecast period, 2018 to 2023. North America dominates the market, due to growing prevalence of cervical cancer diseases and rising awareness regarding cervical cancer in the region.

Favorable Governmental Initiatives toward Cervical Cancer Prevention

The United States assists with coverage and reimbursement on Pap test screening. Federal law has been passed by the Affordable Care Act (ACA) to mandate the coverage of cervical cancer screening tests. It is also supported by self-insured plans. Medicaid, the most popular government insurance program covers screening for cervical cancers. Medicare, another widely used insurance covers Pap test, pelvic exam, and a clinical breast exam for cervical cancer screening every two years for Medicare beneficiaries. There are also support programs like National Breast and Cervical Cancer Early Detection Program (NBCCEDP), which provides cervical cancer screening to women without health insurance for free or at very little cost. According to the Federal Advisory Committee on Immunization Practices (ACIP) recommendations, the US government is trying to include HPV vaccine in the insurance plans and include it as a part of federal Vaccine for Children (VFC) entitlement program. All these governmental initiatives toward cervical cancer prevention have led to the growth of the market.Additionally, growing prevalence of cervical cancer, increasing awareness regarding early diagnosis, and strong R&D from key players for cervical cancer diagnosis and drugs are anticipated to drive the market of global cervical cancer diagnostics and therapeutics.

Economic Constraints in Many Countries to Adopt Regular Testing Procedures

In middle-income and low-income developing countries, the existing programs are failing to create major impact. This failure is mostly attributed to the lack of or in many cases the absence of a healthcare system that is capable of providing the diagnostic and treatment services inseparable from screening. Many countries of Asia-Pacific and Africa lack a proper healthcare infrastructure to provide the basic medical amenities to people living in rural, and underdeveloped areas. For such remote and hard areas where there is also a social stigma to undergo medical tests, a government or NGO-funded screening program is hard to implement. There is also a definite lack of trained healthcare professionals and a lack of awareness among the people of this region to help achieve an effective implementation of screening programs. Thus, the economic and social constraint in this region will be a major restraint for the major market players trying to invest in this region, which might impede the growth of the global cervical cancer diagnostics and therapeutics market.

Asia-Pacific Expected to Grow Tremendously

Asia-Pacific is expected to grow tremendously during the forecast period, owing to factors, such as high prevalence of cervical cancer. The high prevalence rate of cervical cancer among the population has attributed to factors, such as less awareness regarding sexual hygiene and precaution. High prevalence of cervical cancer, coupled with a greater government emphasis on screening and improvements in diagnosis of cervical cancer are anticipated to boost the market growth in Asia Pacific.

Key Developments in the Market

September 2017: QIAGEN N.V., launched QIAsure Methylation Test, a novel CE-marked molecular diagnostic test for use in differentiating patient's risk of developing cervical cancer.

May 2016: Advaxis Inc. and Bristol-Myers Squibb announced clinical collaboration to evaluate ADXS-DUAL, immunotherapy targeting HPV-associated cancers, and Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), as a potential combination treatment for women with metastatic cervical cancer.

Major Players: ABBOTT., ADVAXIS, INC., BECTON, DICKINSON, AND COMPANY, BRISTOL-MEYRS SQUIBB COMPANY, F. HOFFMANN-LA ROCHE LTD., GLAXOSMITHKLINE PLC, QIAGEN N.V, MERCK & CO., INC., PFIZER INC., QUEST DIAGNOSTICS INC., amongst others.

Reasons to Purchase this Report

Current and future global cervical cancer diagnostics and therapeutics market outlook in the developed and emerging markets

Analysis of various perspectives of the market with the help of Porter's five forces analysis

The segment that is expected to dominate the market

Regions that are expected to witness the fastest growth during the forecast period

Identify the latest developments, market shares, and strategies employed by the major market players

3 months analyst support, along with the Market Estimate sheet (in excel)

Customization of the Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitute Product and Services
    • 5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Favorable Governmental Initiatives Toward Cervical Cancer Prevention
    • 6.1.2 Growing Prevalence of Cervical Cancer
    • 6.1.3 Increase of Awareness Regarding Early Diagnosis
    • 6.1.4 Strong R&D from Key Players for Cervical Cancer Diagnosis and Drugs
  • 6.2 Market Restraints
    • 6.2.1 Economic Constraints in many Countries to Adopt Regular Testing Procedures
    • 6.2.2 High Cost of Cancer Therapies
  • 6.3 Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 By Diagnostic Test
    • 7.1.1 Pap Smear Test
    • 7.1.2 HPV Test
    • 7.1.3 Colposcopy
    • 7.1.4 Biopsy and Endocervical Curettage
    • 7.1.5 Others
  • 7.2 By Therapeutic
    • 7.2.1 Avastin (Bevacizumab)
    • 7.2.2 Blenoxane (Bleomycin)
    • 7.2.3 Hycamtin (Topotecan Hydrochloride)
    • 7.2.4 Gemcitabine-Cisplatin
    • 7.2.5 Vaccines
      • 7.2.5.1 Gardasil
      • 7.2.5.2 Cevarix
  • 7.3 By End User
    • 7.3.1 Hospitals
    • 7.3.2 Specilty Clinics
    • 7.3.3 Cancer and Radiation Therapy Centers
    • 7.3.4 Diagnostics Centers
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 United States
      • 7.4.1.2 Canada
      • 7.4.1.3 Mexico
    • 7.4.2 Europe
      • 7.4.2.1 France
      • 7.4.2.2 Germany
      • 7.4.2.3 United Kingdom
      • 7.4.2.4 Italy
      • 7.4.2.5 Spain
      • 7.4.2.6 Rest Of Europe
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 China
      • 7.4.3.2 Japan
      • 7.4.3.3 India
      • 7.4.3.4 Australia & New Zealand
      • 7.4.3.5 South Korea
      • 7.4.3.6 Rest of Asia-Pacific
    • 7.4.4 Middle East & Africa
      • 7.4.4.1 GCC
      • 7.4.4.2 South Africa
      • 7.4.4.3 Rest of the Middle East & Africa
    • 7.4.5 South America
      • 7.4.5.1 Brazil
      • 7.4.5.2 Argentina
      • 7.4.5.3 Rest of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations, and Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 Abbott.
  • 9.2 Advaxis, Inc.
  • 9.3 Becton, Dickinson and Company
  • 9.4 Bristol-Meyrs Squibb Company
  • 9.5 F. Hoffmann-La Roche Ltd
  • 9.6 GlaxoSmithKline plc
  • 9.7 Merck & Co., Inc.
  • 9.8 Pfizer Inc.
  • 9.9 Qiagen N.V
  • 9.10 Quest Diagnostics Inc
  • 9.11 Others

10. Future of the Market

Back to Top